Yan Zhuang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Interests
Yan Zhuang has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Guoliang Liao
College of Biomedical Engineering, Sichuan University, Chengdu 610065, China
2 shared publications - Jiangli Lin
College of Biomedical Engineering, Sichuan University, Chengdu, China
2 shared publications Ke Chen
2 shared publications- Lin Han
College of Biomedical Engineering, Sichuan University, Chengdu, 610065, Sichuan, China; Highong Intellimage Medical Technology (Tianjin) Co., Ltd, Tianjin, China
2 shared publications Rui Wang
2 shared publicationsCheng Li
China-Japan Friendship Hospital, Beijing, P. R. China
1 shared publication
Latest Publications
- 2 August 2025
- Published by Elsevier in Biomedical Signal Processing and Control
- Vol. 111
TVPNet: Text-vision prompt guided segmentation for small 3D medical object
- 2 August 2025
- Published by Elsevier in Biomedical Signal Processing and Control
- Vol. 111
TVPNet: Text-vision prompt guided segmentation for small 3D medical object
- 26 February 2025
- Published by Elsevier in Neurocomputing
- Vol. 634
Unsupervised visual similarity-based medical image retrieval via dual-encoder and metric learning
- 26 February 2025
- Published by Elsevier in Neurocomputing
- Vol. 634
Unsupervised visual similarity-based medical image retrieval via dual-encoder and metric learning
- 3 July 2024
- Published by World Scientific Pub Co Pte Ltd in Journal of Computational Biophysics and Chemistry
- Vol. 23 (06) , 801-814
Feature Selection and Classification Technique for Predicting Lymph Node Metastasis of Papillary Thyroid Carcinoma
Papillary thyroid carcinoma (PTC) is typically an indolent cancer, yet a minority of cases develop lymph node metastasis. Due to the unclear mechanisms of lymph node metastasis, a considerable number of patients undergo unnecessary surgeries. Currently, the identification of key genetic biomarkers in high-dimensional data presents a significant challenge, thereby limiting research progress in this area. Here, we proposed a hybrid filter-wrapper feature selection strategy for core factor detection and developed MethyAE, a metastasis prediction model based on DNA methylation, utilizing an end-to-end learning auto-encoder. 46 methylated CpG sites were successfully identified as crucial biomarkers for lymph node metastasis. Leveraging 447 PTC samples from the Cancer Genome Atlas (221 with metastasis, 226 without), the MethyAE model achieves 88.9% accuracy and a recall rate of 88.6% in predicting lymph node metastasis, outperforming commonly used machine learning methods like logistic regression and random forest. Furthermore, the MethyAE model exhibits favorable performance in DNA methylation data from colon cancer, bladder cancer, and breast cancer. To the best of our knowledge, this is the first attempt to predict PTC lymph node metastasis through DNA methylation, offering pivotal decision-making criteria for avoiding unnecessary surgeries and selecting appropriate treatment plans for a substantial cohort of PTC patients.
- 3 July 2024
- Published by World Scientific Pub Co Pte Ltd in Journal of Computational Biophysics and Chemistry
- Vol. 23 (06) , 801-814
Feature Selection and Classification Technique for Predicting Lymph Node Metastasis of Papillary Thyroid Carcinoma
Papillary thyroid carcinoma (PTC) is typically an indolent cancer, yet a minority of cases develop lymph node metastasis. Due to the unclear mechanisms of lymph node metastasis, a considerable number of patients undergo unnecessary surgeries. Currently, the identification of key genetic biomarkers in high-dimensional data presents a significant challenge, thereby limiting research progress in this area. Here, we proposed a hybrid filter-wrapper feature selection strategy for core factor detection and developed MethyAE, a metastasis prediction model based on DNA methylation, utilizing an end-to-end learning auto-encoder. 46 methylated CpG sites were successfully identified as crucial biomarkers for lymph node metastasis. Leveraging 447 PTC samples from the Cancer Genome Atlas (221 with metastasis, 226 without), the MethyAE model achieves 88.9% accuracy and a recall rate of 88.6% in predicting lymph node metastasis, outperforming commonly used machine learning methods like logistic regression and random forest. Furthermore, the MethyAE model exhibits favorable performance in DNA methylation data from colon cancer, bladder cancer, and breast cancer. To the best of our knowledge, this is the first attempt to predict PTC lymph node metastasis through DNA methylation, offering pivotal decision-making criteria for avoiding unnecessary surgeries and selecting appropriate treatment plans for a substantial cohort of PTC patients.